Savara Inc (SVRA) Director Sells $277,500.00 in Stock

Share on StockTwits

Savara Inc (NASDAQ:SVRA) Director Richard J. Hawkins sold 25,000 shares of Savara stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $11.10, for a total transaction of $277,500.00. Following the completion of the sale, the director now owns 21,682 shares in the company, valued at approximately $240,670.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

NASDAQ SVRA traded down $0.22 during trading hours on Friday, hitting $11.48. 223,804 shares of the company’s stock traded hands, compared to its average volume of 336,949. Savara Inc has a 52-week low of $6.21 and a 52-week high of $14.06. The stock has a market cap of $405.24 million, a PE ratio of -8.90 and a beta of 1.07. The company has a current ratio of 12.05, a quick ratio of 15.63 and a debt-to-equity ratio of 0.24.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.05. On average, sell-side analysts forecast that Savara Inc will post -1.6 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. MetLife Investment Advisors LLC purchased a new stake in Savara during the 1st quarter valued at about $116,000. Metropolitan Life Insurance Co NY purchased a new stake in Savara during the 1st quarter valued at about $83,000. Geode Capital Management LLC grew its stake in Savara by 5.5% during the 1st quarter. Geode Capital Management LLC now owns 327,537 shares of the company’s stock valued at $2,413,000 after acquiring an additional 17,039 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Savara during the 1st quarter valued at about $466,000. Finally, The Manufacturers Life Insurance Company grew its stake in Savara by 12.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 11,550 shares of the company’s stock valued at $85,000 after acquiring an additional 1,279 shares in the last quarter. 47.99% of the stock is owned by institutional investors.

Several brokerages have recently issued reports on SVRA. Zacks Investment Research lowered shares of Savara from a “buy” rating to a “hold” rating in a research report on Friday. Roth Capital set a $10.00 target price on shares of Savara and gave the company a “hold” rating in a research report on Tuesday. ValuEngine upgraded shares of Savara from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating on shares of Savara in a research report on Friday, May 10th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $21.17.

COPYRIGHT VIOLATION NOTICE: “Savara Inc (SVRA) Director Sells $277,500.00 in Stock” was first reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://macondaily.com/2019/05/17/savara-inc-svra-director-sells-277500-00-in-stock.html.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Read More: What Are Treasury Bonds?

Insider Buying and Selling by Quarter for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.